In addition, it is needed to evaluate sildenafil’s effect in PBMCs from patients with elevated OPN levels (type 2 diabetes, cardiovascular diseases, liver diseases, some autoimmune diseases, etc.). This evidence concerns the gene SPP1 and cardiovascular disorder.